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Abstract: Due to the fact that some individuals are allergic to crustaceans, the presumed 
relationship  between  allergy  and  the  presence  of  chitin  in  crustaceans  has  been 
investigated. In vivo, chitin is part of complex structures with other organic and inorganic 
compounds: in arthropods chitin is covalently linked to proteins and tanned by quinones, in 
fungi it is covalently linked to  glucans, while  in  bacteria  chitin is diversely  combined 
according to Gram(+/-) classification. On the other hand, isolated, purified chitin is a plain 
polysaccharide  that,  at  the  nano  level,  presents  itself  as  a  highly  associated  structure, 
recently refined in terms of regularity, nature of bonds, crystallinity degree and unusual 
colloidal behavior. Chitins and modified chitins exert a number of beneficial actions, i.e., 
(i) they stimulate macrophages by interacting with receptors on the macrophage surface 
that  mediate  the  internalization  of  chitin  particles  to  be  degraded  by  lysozyme  and  
N-acetyl-β-glucosaminidase (such as Nod-like, Toll-like, lectin, Dectin-1, leukotriene 134 
and mannose receptors); (ii) the macrophages produce cytokines and other compounds that 
confer  non-specific  host  resistance  against  bacterial  and  viral  infections,  and  
anti-tumor activity; (iii) chitin is a strong Th1 adjuvant that up-regulates Th1 immunity 
induced  by  heat-killed  Mycobacterium  bovis,  while  down-  regulating  Th2  immunity 
induced by mycobacterial protein; (iv) direct intranasal application of chitin microparticles 
into  the  lung  was  also  able  to  significantly  down-regulate  allergic  response  to 
Dermatophagoids pteronyssinus and Aspergillus fumigatus in a murine model of allergy; 
(v) chitin microparticles had a beneficial effect in preventing and treating histopathologic 
changes in the airways of asthmatic mice; (vi) authors support the fact that chitin depresses 
the development of adaptive type 2 allergic responses. Since the expression of chitinases, 
chitrotriosidase and chitinase-like proteins is greatly amplified during many infections and 
diseases,  the  common  feature  of  chitinase-like  proteins  and  chitinase  activity  in  all 
organisms appears to be the biochemical defense of the host. Unfortunately, conceptual 
and methodological errors are present in certain recent articles dealing with chitin and 
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allergy,  i.e.,  (1)  omitted  consideration  of  mammalian  chitinase  and/or  chitotriosidase 
secretion, accompanied by inactive chitinase-like proteins, as an ancestral defensive means 
against invasion, capable to prevent the insurgence of allergy; (2) omitted consideration of 
the fact that the mammalian organism recognizes more promptly the secreted water soluble 
chitinase produced by a pathogen, rather than the insoluble and well protected chitin within 
the pathogen itself; (3) superficial and incomplete reports and investigations on chitin as an 
allergen, without mentioning the potent allergen from crustacean flesh, tropomyosine; (4) 
limited perception of the importance of the chemical/biochemical characteristics of the 
isolated chitin or chitosan for the replication of experiments and optimization of results; 
and (5) lack of interdisciplinarity. There is quite a large body of knowledge today on the 
use of chitosans as biomaterials, and more specifically as drug carriers for a variety of 
applications: the delivery routes being the same as those adopted for the immunological 
studies. Said articles, that devote attention to the safety and biocompatibility aspects, never 
reported intolerance or allergy in individuals and animals, even when the quantities of 
chitosan used in single experiments were quite large. Therefore, it is concluded that crab, 
shrimp, prawn and lobster chitins, as well as chitosans of all grades, once purified, should 
not  be  considered  as  "crustacean  derivatives",  because  the  isolation  procedures  have 
removed proteins, fats and other contaminants to such an extent as to allow them to be 
classified as chemicals regardless of their origin. 
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Acronyms 
 
AAM,  alternatively  activated  macrophage;  AMCase,  acidic  mammalian  chitinase;  CBP,  chitin 
binding  protein;  CHI3L1,  chitinase  3-like-1;  CLP,  chitin-like  protein;  Ig,  immunoglobulin;  IL, 
interleukin;  INF,  interferon;  LPS,  lipopolysaccharide;  NAGase,  N-acetylglucosaminidase;  PEG, 
poly(ethylene glicol); TGF, transforming growth factor; Th, T helper; TLR, toll-like receptor; TNF, 
tumor necrosis factor 
 
1. Introduction 
 
1.1. Recognition, allergy and asthma 
 
Immunity  against  microbial  pathogens  primarily  depends  on  the  recognition  of  pathogen 
components by innate receptors expressed on immune and non-immune cells. Innate receptors are 
evolutionarily  conserved  proteins  that  recognize  pathogens  or  products  released  by  pathogens  in 
different cellular compartments, such as the plasma membrane, the endosomes or the cytoplasm, and 
induce the expression of cytokines, chemokines and co-stimulatory compounds to eliminate pathogens 
and impart pathogen-specific adaptive immune responses.  Mar. Drugs 2010, 8 
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Acute  allergic  sensitization  in  individuals  involves  Th2  cell  expansion  following  exposure  to 
allergens. Th2 cells secrete a multitude of cytokines, including IL-4, IL-5, IL-9 and IL-13, as well as 
chemokines such as thymus and activation-regulated chemokine and macrophage-derived chemokine, 
leading to further Th2 cell recruitment and activation of B cells. Under the influence of IL-4, B cells 
produce allergen-specific IgE that circulates and binds surface receptors on mast cells and basophils. 
Further exposure to allergen results in crosslinking of IgE on mast cells and basophils causing cell 
degranulation, releasing histamine, proteases, chemokines, prostoglandins, leukotrienes and a host of 
other  mediators.  This  results  in  bronchoconstriction  and  recruitment  of  activated  eosinophils, 
neutrophils, lymphocytes and macrophages. In some individuals, chronic allergic reactivity manifests 
as asthma due to airway wall remodeling, airways hyperresponsiveness and chronic inflammation. The 
allergic immune response was reviewed by Larche [1,2]. 
 
1.2. Chemistry of chitin associations in vivo and chitin isolates 
 
There are several chitins of marine origin, but those commonly available from fishing activities are 
from crustaceans and squids. As described by Muzzarelli, they substantially differ from each other in 
terms  of  crystallinity;  the  crustacean  chitins  having  the  alpha  polymorphic  form,  while  the  squid 
chitins exhibit the beta form that confers more versatility in chemical derivatization [3,4].  
The present review article deals with crustacean chitins only, owing to the fact that the title matter 
is directly related to crustaceans. Because some individuals are allergic to crustaceans, some scientists 
have been prompted to investigate the presumed relationship between allergy and  the presence of 
chitin in the crustaceans. For the first time in the scientific history of chitin, the well-assessed safety of 
chitin  for  the  human  organism  has  been  questioned  with  unusually  dramatic  titles  and  figures  of 
several articles. The problem has been set forth on a vague scientific basis, but with potential negative 
consequences on the exploitation of the chitin resources that derive from the industrial production of 
canned or frozen crustaceans. 
While today, purified chitin itself can be used for some applications, in general its derivatives 
chitosan  (obtained  after  deacetylation),  chitooligomers  (after  partial  depolymerization)  and 
glucosamine with N-acetylglucosamine (after full depolymerization) are used in the biomedical field. 
These  medical  grade  chemicals  are  further  modified  in  many  ways  in  order  to  optimize  their 
performances. Indeed, they are refined carbohydrates with clearly described characteristic properties, 
and it would be unreasonable to see them as crustacean derivatives, even though their origin should be 
traceable. Even isolated chitin is a substance totally different from the chitin present in vivo, that is part 
of  a  complex  structure  with  other  organic  and  inorganic  compounds.  No  instrumental  analytical 
technique  can  identify  the  raw  material  from  which  a  given  sample  of  isolated  chitin  has  been 
produced. 
This is not a peculiarity of chitin, in any case. For example, maize starch commonly used for human 
consumption, is not regarded as a part of the maize plant: the extraction process of maize starch from 
the kernel is a process known as wet milling in which the starch is separated from the fiber, oil and 
protein. Similarly, with the aid of aggressive chemicals in a series of processes, chitin is separated 
from  calcium  carbonate,  proteins  and  carotenoids.  Both  starch  and  chitin  are  the  refined/purified Mar. Drugs 2010, 8 
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polysaccharides with no more relationship with the respective living organisms that biosynthesized 
them.  
Therefore, at the nano level, chitin is a highly associated structure that has been recently refined in 
terms of regularity, nature of bonds, crystallinity degree and other parameters. Certain laboratories 
have provided most valid and realistic description of the status of chitin in the crustaceans [5–7]. Two 
book chapters by Muzzarelli are useful for the comprehension of the structure of the arthropod cuticle 
and provide the essentials for the correct understanding of chitin and chitinases [8,9]. 
 
2. The Beneficial Activity of Chitin as an Immunoadjuvant 
 
Nearly three decades ago, Suzuki et al. and Nishimura et al. demonstrated that chitin and chitin 
derivatives  stimulate  macrophages  to  produce  cytokines  that  confer  anti-tumor  activity  and  non-
specific  host  resistance  against  bacterial  and  viral  infections  [10–14].  Since  then,  more  specific 
immunologic activities of chitin have been reported. Shibata et al. re-evaluated the immunological 
effects of chitin in vivo and in vitro using phagocytosable small-sized chitin particles that demonstrated 
significant  priming  effects  of  chitin  particles  in  alveolar  macrophages  and  NK  cells  in  mice: 
intravenous administration of fractionated chitin particles (1 to 10 μm) into the lung activates alveolar 
macrophages to express cytokines such as IL-12, tumor necrosis factor-α (TNFα), and IL-18, leading 
to INF-γ production mainly by NK cells [15]. Further studies by the same authors demonstrated that 
the  cytokine  production  was  through  phagocytosis  mediated  by  a  mannose  receptor  [16].  The 
macrophage plasma membrane mannose receptors serve to mediate the internalization of the chitin 
particles that then are degraded by lysozyme and N-acetyl-β-glucosaminidase in the macrophages of 
human and experimental animals according to Bourbouze et al. [17]. The immunological aspects of 
chitin and chitin derivatives administered to animals were studied by Tokura et al. [18]. The studies 
cited  here  were  the  first  demonstration  of  the  direct  interactions  between  chitin  and  cell  surface 
receptors and indicated that chitin uses specific signaling pathways in immune regulation. Lee further 
demonstrated that chitin stimulates macrophages by interacting with different cell surface receptors 
such as macrophage mannose receptor, toll-like receptor-2 (TLR-2), C-type lectin receptor Dectin-1, 
and leukotriene 134 receptor (BLT1) [19]. The advances in the study of pathogen recognition and their 
signaling pathways have been discussed most recently [20–22]. 
The ample evidence that chitin is a potent innate immune stimulator of macrophages and other 
innate immune cells raises the possibility that chitin could affect allergen-induced adaptive type 2 
responses as well, but, generally, type 1 cytokines are produced by innate immune cells and it has been 
shown that type I cytokines down-regulate type 2 allergic immune responses [23]. In addition, the 
administration of IFN-γ or IL-12 significantly inhibited Th2 driven inflammatory responses in allergic 
animal  models  [24,25].  Thus,  it  is  reasonable  that  chitin  depresses  allergen-induced  type  2 
inflammatory  responses.  Several  studies  strongly  support  this  approach.  Shibata  et  al.  have 
demonstrated  that  orally  given  chitin  down-  regulates  allergen-induced  IgE  production  and  lung 
inflammation in a ragweed-immunized allergic animal model [23]. The allergen-stimulated production 
of Th2 cytokines, such as IL-4, IL-5, and IL-10 was inhibited by the presence of chitin in spleen cell 
culture. The IFN-γ produced by NK cells and Th1 cells was responsible for the inhibition of allergen-
induced Th2 cytokine production. They have also shown that chitin is a strong Th1 adjuvant that up-Mar. Drugs 2010, 8 
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regulates  Th1  immunity  induced  by  heat-killed  Mycobacterium  bovis,  while  down  regulating  Th2 
immunity induced by mycobacterial protein [26]. The Th1 adjuvant effect of chitin microparticles in 
inducing viral specific immunity has also been reported by Hamajima et al. [27]. 
Strong et al. showed that direct intranasal application of chitin microparticles into the lung also 
significantly  down-regulated  allergic  response  to  Dermatophagoids  pteronyssinus  and  Aspergillus 
fumigatus in a murine model of allergy [28]. The chitin treatment substantially reduced the allergen-
induced  serum  IgE  levels,  peripheral  eosinophilia,  airway  hyper-responsiveness,  and  lung 
inflammation. They noted the elevation of Th1 cytokines IL-12, IFN-γ and TNF-α and reduction in  
IL-4 production in the chitin-treated mice compared to sham controls. Similarly, intranasal application 
of  water  soluble  chitosan  attenuated  mucus  production  and  lung  inflammation  induced  by 
Dermatophagoids farinae.  
Ozdemir  et  al.  further  demonstrated  that  application  of  microgram  quantities  of  chitin 
microparticles had a beneficial effect in preventing and treating histopathologic changes in the airways 
of  asthmatic  mice  [29].  All  these  studies  strongly  support  the  fact  that  chitin  depresses  the 
development of adaptive type 2 allergic responses. As a regulatory mechanism, down regulation of 
allergen-induced arginase I and thymic stromal lymphopoietin expression in the bronchial epithelium 
was suggested and discussed [30–32]. From the clinical point of view, the regulatory function of chitin 
on Th2 adaptive immune response is therapeutically important because it can be applied to control a 
variety of type 2 allergic diseases. These data indicate that the administration of chitin is beneficial 
(instead of dangerous) because it exerts immunoadjuvant effect, and depresses the insurgence of Th2 
allergy. Shrimp chitin is therefore a potent T and B cell adjuvant when delivered in the form of chitin 
microparticles and can shift a polarized T-helper type 2 (Th2) immune response [allergy] towards a 
Th1 response [inflammation]. 
Advances made in the last quinquennium in the way of thinking about the chitin/chitinase/chitin-
like proteins subject, can be illustrated by the contributions made by the Elias team, through a number 
of articles. In an introductory note to the article by Zhu et al. on the acidic mammalian chitinase in 
asthmatic Th2 inflammation [33], Couzin recommended caution in the interpretation of the available 
data  "because  something  is  missing"  [34].  Then,  the  concept  that  asthma  might  be  a  parasite-
independent antiparasite response was introduced by Elias et al. [35]; they compared the clinical data 
on chitinase 3-like-1 levels of certain groups of patients with severe asthma [36], and reminded that the 
chitinase 3-like-1 (otherwise called human cartilage glycoprotein-39, HCgp-39, or YKL-40) is also 
present in patients with meningitis, pneumonia, rheumatoid arthritis, osteoarthritis, breast and lung 
cancer,  and  hepatic  fibrosis.  Incidentally,  abundant  literature  is  available  on  the  presence  of  the 
chitinolytic  enzyme  N-acetylglucosaminidase  in  patients  suffering  from  most  various  diseases  or 
particular physiological situations in which chitin is certainly not involved (for a review see [37]). 
They also underlined that antigens that contain chitin (dust mite D. pteronyssinus) and antigens that do 
not contain chitin (rye and birch) induce similar responses [38]. 
Lee et al. and DaSilva et al. reviewed the beneficial immunostimulating activity of chitin, and 
demonstrated that the chitin activity depends on the size of its particles (higher when particles are  
2–10 micron) [39,40]. Most recently they reviewed the field of chitinase-like proteins whose main 
value resides in being novel biomarkers in asthma [41]. 
 Mar. Drugs 2010, 8 
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3. Chitinases and Chitinase-Like Proteins in Mammals  
 
Mammals  produce  chitinases,  and  their  increased  secretion  is  closely  associated  with 
pathophysiological conditions dominated by T-helper type 2 cells (Th2) including infection, fibrosis, 
allergy and asthma [33,42,43]. The review by Sutherland et al. gives a broad perspective of the effects 
and functions of chitinases and CLPs in the context of their association with allergy and asthma [44]. 
Studies on chitinases in lower organisms may provide some interesting parallels for understanding the 
function of the mammalian chitinases and CLPs. The action and pattern of chitinase expression in 
plants, bacteria, viruses and fungi illustrate a number of diverse roles in morphogenesis, nutrition, 
defense and stress [45]. 
The most common feature of chitinase activity in all organisms appears to be the biochemical host 
defense against chitin-containing pathogens. In fact, in mammals, expression of chitinases and CLPs is 
greatly  amplified  during  many  infections  [46].  Indeed,  the  chitinase-like  protein,  Ym1,  was  first 
reported as a prominent novel product in mice infected with the helminths Trichinella spiralis, Brugia 
malayi and Schistosoma mansoni [47–49]. 
The Ym1 production is strikingly associated with a distinct cell phenotype termed the alternatively 
activated macrophage (AAM). High levels of IL-4 and IL-13 in Th2-driven inflammatory settings of 
infection and allergy stimulate abundant numbers of AAMs [50] which also up-regulate resistin-like 
molecule-a,  arginase-1  and  the  mannose  receptor  [51].  Hence,  while  fungal  infections  with 
Cryptococcus  neoformans  are  normally  limited  by  a  Th1  response,  in  IFN-γ-deficient  and  IL-13 
overexpressing  mice  there  is  a  dominant  Th2  response  accompanied  by  alternative  activation  of 
macrophages and production of Ym1, associated with more severe disease [52, 53]. 
The abundant secretion of Ym1 by murine AAMs and alveolar macrophages suggests that it is 
required in some quantity to fulfil an as yet undefined role in inflammation and repair because Ym1 
binds components of the extracellular matrix. One might speculate that chitinases and CLPs, through 
interactions with the extracellular matrix and host sugars, provide a physical basis for tissue repair and 
remodeling, appropriately during helminth infection and inappropriately during asthma. 
Chitinases  and  CLPs  are  certainly  prominent  in  the  human  response  to  infection,  and  human 
alveolar  macrophages  from  allergic  or  asthmatic  patients express  the  acidic  mammalian  chitinase, 
AMCase, which is also seen in mouse models of helminth infection and allergy. Elevated chitinase 
activity and/or protein levels in humans implicate AMCase, chitrotriosidase and chitinase 3-like-1 in 
severe infections. Human plasma levels of chitrotriosidase activity increase upon infection with fungal 
pathogens and malaria parasites, consistent with an involvement in host defense [54–56].  
The roles of chitinases and CLPs in human host defense thus remain unresolved. From current 
knowledge it would appear that both chitinases and CLPs are strongly associated with both innate and 
adaptive immune responses, but direct evidence is still lacking that they play an effector role in anti-
parasite immunity. Whether their primary function is in the context of protective immunity, or tissue 
repair, in different contexts these proteins may be either beneficial or detrimental for the host. 
 Mar. Drugs 2010, 8 
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4. Misleading Statements and Sources of Errors 
 
Chitin has been directly associated to asthma in a couple of articles on a rather arbitrary basis by 
Burton & Zaccone and by Dickey [57, 58]. The close examination of these articles indicates that the 
authors equivocated about the chemical form of chitins occurring in vivo. It is apparent that a number 
of  authors  are  not  familiar  with  books  and  articles  describing  the  structure  and  the 
chemical/biochemical combinations of chitin in vivo, and they arbitrarily assumed that chitin in mites, 
worms, fungi and bacteria is something similar to the packaged chitin supplied by industrial producers. 
Basic books [59–67] do not appear to have been cited in their articles.  
The animal/human organism has an alert system that detects pathogens, but it is highly questionable 
that isolated chitin itself could trigger and sustain a series of biochemical reactions leading to allergy 
and asthma particularly when said chitin is a part of a biological structure. In fungi, chitin is covalently 
linked to glucans, while in arthropods it is covalently linked to proteins and tanned by quinones; in 
bacteria chitin is diversely combined according to Gram(+/-) classification.  
Therefore, illustrations and text in the article by Burton & Zaccone [57] are misleading because 
they translate the images of arthropods, fungi and helminths into the chitin chemical formula; it is 
stated  there  that  "exposure  to  chitin  from  dust  mites,  moulds,  shellfish  and  insects  might  be  the 
primary  external  determinant  in  allergy  development"  without  providing  experimental  proof. 
Similarly, Figure 1 and the corresponding legend in the article by Dickey [58] interpret the images of 
mites, fungi and helminths as chitin whose formula is placed in the middle of an "alveolus" in such a 
way  as  to  give  the  impression  that  chitin  is  responsible  for  allergic inflammation  in  the  airways. 
Rudimentary  and  approximate  is  the  analogous  Figure  1  in  the  review  by  Shuhui  et  al.  [68]. 
Remarkably, all these authors forget to add bacteria to the list. 
As said above,  purified chitin is  certainly  an immunoadjuvant, but  the  aspect  that escaped  the 
observation  of  many  research  workers  is  the  mechanism  by  which  chitin-bearing  pathogens  are 
recognized by  the  mammalian  organism:  it  is  a  well  assessed  fact  that  bacteria,  mites,  fungi  and 
nematodes are recognized. Hong et al. [69] investigated the direct effects of exogenous chitinase from 
Streptomyces griseus on Ca
2+ signaling in human airway epithelial cells: the exogenous chitinase was 
found  to  cleave  a  model  peptide  representing  the  cleavage  site  of  protease-activated  receptor-2  
(PAR-2) and enhanced IL-8 production. These results indicate that exogenous chitinase is a potent 
proteolytic activator of PAR-2 that can directly induce Ca
2+ signaling in human airway epithelial cells. 
The meaning of this is that the mammalian organism recognizes the secreted water soluble chitinase 
produced by a pathogen, rather than the insoluble and well protected chitin within the same pathogen. 
This  is  followed by the secretion of the  mammalian chitinase  and/or chitotriosidase, as  a  generic 
defensive means against invasion. According to Chen et al. direct inhibition of hyphal growth could be 
achieved  with  the  use  of  AMCase;  in  fact,  they  studied  the  in  vitro  antifungal  activity  of  acidic 
mammalian  chitinase  against  Candida  albicans,  Aspergillus  fumigatus  and  Trichophyton  rubrum 
strains. The growth of all three dermato-pathogenic fungi was clearly inhibited by recombinant and 
natural AMCase, especially the natural one [70].  
For example, the fungal pathogen Candida albicans has a multilayered cell wall composed of an 
outer layer of proteins glycosylated with N- or O-linked mannosyl residues and an inner skeletal layer 
of  β-glucans  combined  with  chitin.  It  was  demonstrated  that  cytokine  production  by  human Mar. Drugs 2010, 8 
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mononuclear cells or murine macrophages was markedly reduced when stimulated by  C. albicans 
mutants defective in mannosylation. Recognition of mannosyl residues was mediated by mannose 
receptor binding to N-linked mannosyl residues, and by TLR4 binding to O-linked mannosyl residues. 
Residual cytokine production was mediated by recognition of β-glucan by the dectin-1/TLR2 receptor 
complex. Recognition of C. albicans by monocytes/macrophages is mediated by three recognition 
systems of differing importance, each sensing specific layers of the C. albicans cell wall, but not  
chitin [71]. 
It  was  found  that  dectin-1  recognizes  C.  albicans  yeast,  but  not  filaments  [72].  Deformities 
produced  in  the  cell  wall  during  budding  expose  patches  of  β-glucan  that  are  recognized  by  the 
receptor. In fact, these patches, identified as bud and birth scars, are sufficient to permit activation of 
dectin-1, and trigger potent antifungal inflammatory responses in macrophages. C. albicans filaments 
do not expose β-glucan in bud scars since mother–daughter cell separation does not occur, and thus 
filamentous C. albicans avoids to activate dectin-1-mediated mammalian defenses. Therefore the C. 
albicans shape alone (not the presence of glucan, even less chitin) contributes to the approach by 
which phagocytes recognize the fungus.  
In humans, distinct membrane Toll-like receptors can directly bind common bacterial components 
such  as  lipopolysaccharides,  bacterial  lipoprotein,  and  peptidoglycan  and  subsequently  initiate  an 
intracellular signaling pathway leading to innate immune gene induction. In Drosophila, the binding 
protein  DGNBP-1  has  high  affinity  to  microbial immune  elicitors  such  as  lipopolysaccharide  and  
β-1,3-glucan  whereas  no  binding  affinity  is  detected  with  peptidoglycan,  β-1,4-glucan,  or  chitin. 
Importantly,  the  overexpression  of  DGNBP-1  in  Drosophila  enhances  lipopolysaccharide-  and  
β-1,3-glucan-induced innate immune gene expression. These results suggest that DGNBP-1 functions 
as a pattern recognition receptor for LPS from Gram(-) bacteria and β-1,3-glucan from fungi and plays 
an  important  role  in  non-self  recognition  and  the  subsequent  immune  signal  transmission  for  the 
induction of antimicrobial peptide genes in the Drosophila innate immune system. Therefore, many 
organisms from humans to insects recognize bacteria without reference to chitin [73]. 
The name chitinase has been abused in some articles as well. The most recent articles correctly 
underline the fact that the compounds under study are deprived of enzymatic activity, i.e., they are 
chitinase-like proteins, but besides the most often mentioned acidic mammalian chitinase (AMCase), 
other enzymes are not mentioned at all, such as N-acetylglucosaminidase, NAGase, which has been the 
object of studies for many years and still appears frequently in the literature. Therefore, even in this 
area, the ongoing studies ignore a large part of the enzymological knowledge gained in this field. The 
enormous  body  of  information  on  NAGase  includes  its  use  as  a  biomarker  of  stress  and  renal 
functionality  in  patients,  and  its  significance  in  key  aspects  of  ecology  such  as  parasitism.  More 
specifically, NAGase is present in the epidermis of crustaceans (under hormonal control) where it is 
responsible for the resorption of chitin in the early stage of the molt. Nevertheless, those authors who 
claimed the involvement of chitin in asthma insurgence in workers exposed to crustaceans, did not care 
about the possible presence of NAGase in those hypothetically inhaled aerosols where they imply that 
insoluble chitin particles are present (not demonstrated). Even worse, they did not pay attention to the 
real  allergens,  tropomyosin  in  primis,  a  soluble  compound  coming  from  crustacean  flesh.  The 
superficiality and incompleteness of these investigations is such that not even a word was spent on Mar. Drugs 2010, 8 
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NAGase and on tropomyosin. This methodological error remained undetected for a long time, and the 
arbitrary equivalence chitin = allergen was taken for granted [74]. 
The claim that fish factory workers may get asthma as a consequence of the exposure to "chitin" 
should be rejected. Based on what was said above, the claim is hardly sustainable in the light of the 
food technology actuated in shrimp and lobster handling: for example, the shrimps (either to be canned 
or to be frozen) are handled by peeling machines with minimal supervision by workers, with minimal 
fragmentation of the shells and with no aerosol dispersion. In those factories, protection of the workers 
and  product  quality  assurance  are  mainly  concerned  with  the  effects  of  proteases  and  recognized 
allergens.  
The major shrimp allergen has been identified as the muscle protein tropomyosin, which is also 
present in other crustaceans (lobsters, prawns and crabs) and a variety of marine organisms, but also in 
insects such as the cockroach and in arachnids such as house dust mites. In certain individuals this 
protein processed by macrophages and presented to T and B lymphocytes stimulates the production of 
protein-specific  IgE  antibodies  with  consequent  insurgence  of  the  allergy  symptoms.  The 
tropomyosins of various sources are listed in one of the tables in the article by Lehrer et al. [75].  
Shrimp-derived glucosamine is safe even for individuals hypersensitive to tropomyosin. Villacis et 
al. state that glucosamine supplements from various manufacturers do not contain clinically relevant 
levels of allergens [76]. Gray et al. clearly state that "shellfish allergy is caused by IgE antibodies to 
antigens in the flesh of the shellfish and not the shell; therefore it should be safe for patients with 
shellfish allergy to take glucosamine supplements" [77]. 
Another error resides in the belief that any isolated chitin is suitable for research in the medical 
field. Reese T.A. et al. remarked that transgenic mice overexpressing AMCase showed no sign of 
spontaneous inflammation, whilst in a previous report of theirs AMCase was interpreted as a pro-
inflammatory mediator. They expressed the view that AMCase has a role in the feedback attenuation 
of innate immune response against chitin-bearing pathogens, the said response being the enzymatic 
degradation of the pathogen's chitin, thus removing the stimulus for further eosinophil and basophil 
recruitment [78]. The authors administered a chitin suspension to mice intraperitoneally or nasally: 
they wrote that the chitin (catalog code omitted) was supplied by New England Biolabs, but they did 
not mention origin, physico-chemical characteristics, and chemical purity; they simply declared that it 
was washed in phosphate buffer saline, but they did not specify unambiguously the final concentration 
of  chitin  in  suspension.  Surprisingly,  the  referees  did  not  remark  on  such  a  flaw  that  prevents 
replicating the experiment. The claim that unknown quantities of isolated chitin of unknown purity 
induce accumulation in mice  tissue  of innate immune  cells  associated with  allergy [78]  might  be 
unrealistic when referred to the actual quantities of chitin released by parasitic worms during moulting.  
The controversy is also based on the already cited studies [15, 16, 23, 28, 29] that demonstrated that 
chitin was anti-allergenic, reducing allergen-induced increases in BALF eosinophils and lymphocytes, 
IgE levels, Th2 cytokines IL-4 and IL-5, goblet cell hyperplasia and subepithelial fibrosis. The down-
regulatory effects of chitin on the allergic response may be partially due to the induction of Th1 
cytokines. Chitin may induce a Th1 response in allergic animals to antagonize an already primed Th2 
response. It is thus possible that an increase in chitin due to chitinase inhibition does not result in 
adverse effects in individuals already allergic. Mar. Drugs 2010, 8 
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Another error was to disregard the study of chitotriosidase, which was the first to be described as a 
human  chitinase,  according  to  the  abundant  literature  on  this  enzyme.  As  a  matter  of  fact, 
chitotriosidase did not appear in the literature mentioned here until 2007 when Barone et al. published 
a review [79]. In late November 2008, Seibold et al. published an article [80] on chitotriosidase as the 
primary active chitinase in the human lung, modulated by genotype and smoking habit. They stated 
that: (1) = the chitinase activity in broncho-alveolar lavage fluids matched that of chitotriosidase but 
not  that  of  AMCase;  (2)  =  AMCase  transcripts  in  macrophages  were  consistent  with  an  isoform 
lacking enzymatic activity; (3) = the chitinase activity in lavage fluids tended to be lower than normal 
in asthmatic subjects, but was increased 7-fold in habitual smokers; and (4) = chitinase activity did not 
increase in subjects with asthma and in fact tends to be decreased. Indeed, such results invalidated 
most of the previous research results, insofar as the major mammalian chitinase, chitotriosidase, was 
disregarded by all previous research workers, who attributed enzymatic activity to AMCase, which on 
the contrary might be present as an isoform deprived of enzymatic activity. Moreover, the asthmatic 
patients had lower-than-normal chitinase, whilst smokers had seven-fold higher. Here the importance 
of cigarette smoking is at the same level as the diesel exhaust mentioned [81] and the toxicity of 
diisocyanates. 
 
5. Novel Views from Experimental Evidence 
 
While studying the inflamed colon in the dextran sulfate-induced colitis model, the Mizoguchi lab 
found upregulated gene expression of chitinase 3-like-1 in colonic epithelial cells and macrophages in 
the inflamed colon: they demonstrated that chitinase 3-like-1 exacerbates intestinal inflammation by 
facilitating bacterial adhesion and invasion into the intestinal mucosa and the development of acute 
colitis [82,83]. No chitin/chitosan was used in these investigations. Neutralization of CHI3L1 in vivo 
ameliorated the induced colitis. Nevertheless, it is unlikely that CHI3L1 recognizes bacterial cells via 
their chitin component, because the external surface of the bacterium is essentially anionic due to the 
presence  of  teichoic  acids  and  phosphorylated  compounds,  and  because  chitin  is  protected  by 
glycoproteins and glucans. Interestingly, a positive correlation between serum CHI3L1 and C-reactive 
protein  levels  (CRP  being  an  inflammation  marker)  was  previously  reported  in  ulcerative  colitis 
patients. Therefore, it was deduced that CHI3L1 is upregulated in acute and chronic colitis: in fact, 
endogenous  CHI3L1  mRNA  level  was  found  to  be  upregulated  after  the  stimulation  with  pro-
inflammatory cytokines (TNFα, IL-1β and IL-6) in colonic epithelial cell lines.  The authors were 
extremely cautious when mentioning chitin: for example they wrote that it would be possible that 
CHI3L1 binds to a complex of chitin with chitin-binding proteins that is formed on bacteria and this 
binding may subsequently enhance the adhesion and invasion by bacteria. The claim "through the 
interaction with chitin" [84] was abandoned here and in subsequent 2008 publications by the same 
team. 
In realistic terms, certain proteins could bind to the bacterial surface without involving the chitin. 
As for AMCase, the neutralization of its enzymatic activity in vivo by administration of anti-AMCase 
anti-body or a chitinase inhibitor (allosamidin) significantly alleviated airway inflammation as well as 
airway hyper-responsiveness. That study suggests that AMCase can be targeted to control asthma and Mar. Drugs 2010, 8 
 
 
302 
other forms of Th2-mediated inflammation. On the other hand, if chitin was so powerful to elicit 
inflammation, the authors would have used it instead of dextran sulfate [82]. 
Dysregulated host-microbial interactions play a pivotal role in the pathogenesis of inflammatory 
bowel disease, and there is interest in maintaining the normal bacterial flora. The impression is that the 
chitinase-like proteins (CHI3L1) interact unspecifically with compounds (other than chitin) occurring 
on the bacterial cell surface. The adhesion rate of CBP21-overexpressing non-pathogenic E. coli was 
increased by two-fold in the presence of CHI3L1, that is therefore involved in the enhancement of 
adhesion of CBP-expressing bacteria to colonic epithelial cells. Chitin binding protein-21 (CBP21) and 
its homologs may be required for the CHI3L1-mediated enhancement of bacterial adhesion to colonic 
cells through the conserved amino-acid residues [85]. This is a further indirect evidence that bacterial 
chitin is not directly accessible being part of a complex structure. 
Soon afterwards, the Mizoguchi lab recognized that the oral administration of chitin ameliorates 
chronic colitis: thus, chitin per se can not produce inflammation in this context [86]: this conclusion is 
in full agreement with those of the other teams mentioned above who used chitin to attenuate allergic 
hypersensitivity to pathogens, for example by intranasal application of chitin. A considerable amount 
of  data  exists  on  the  anti-inflammatory  activity  of  chitosan  in  the  lower  intestine  under  similar 
conditions (not discussed here).  
Concisely, the following aspects of the research activity so far examined should be underlined: 
A  =  Lack  of  interdisciplinary  coordination  is  evident.  Specifically,  polysaccharide  chemistry, 
bacteriology, chitin enzymology, and other disciplines were not adequately involved in these studies. 
B = A number of authors have re-directed their research at more finely documented targets, and 
have rectified in part their previous findings, or have attributed more importance to the diagnostic use 
of the data on chitinases. 
C = the chitinase 3-like-1 has been the object of a review article by Coffman who has correctly 
described the countless circumstances in which this protein is expressed (indirectly pointing at the 
scarce significance that occasional exposure to chitin might have on its upregulation) [87]. Moreover, 
the  capacity  of  this  protein  to  interact  with  many  compounds  is  in  favor  of  further  complex 
investigations. 
D = some genetic aspects emerged in the most recent literature: Chatterjee et al. tested 16 allergens, 
some of which exempt from chitin, and carried out a genetic research on the polymorphism of the 
acidic mammalian chitinase gene, CHIA. They established, for the first time, a significant relationship 
of CHIA with atopic asthma and with total IgE levels in serum; they pointed out that ex novo research 
on this gene may clarify the reasons for asthma insurgence [88]. 
Zhang  et  al.,  not  really  involved  with  chitin/chitosan,  studied  a  murine  model  of  asthma 
(ovalbumin-sensitized mice): each animal was sensitized with 20 μg of chicken egg albumin plus 2 mg 
of aluminum hydroxide [81]. These authors had  previously reported that a diesel exhaust particle 
extract  induces  a  linear  increase  in  new  protein  expression.  The  proteins  are  lungkine,  a  recently 
described chemokine, a family of chitinases including Ym1, Ym2, and acidic mammalian chitinase 
(AMCase), gob-5, a protein that mediates mucus secretion, and surfactant protein-D, a lectin capable 
of modulating inflammatory responses. They remained at undetectable levels or at very low levels in 
broncho-alveolar lavage fluid of normal mice, but were abundantly increased in airway inflammation. 
Low levels of oxidative stress-induced antioxidant and cytoprotective responses while higher levels of Mar. Drugs 2010, 8 
 
 
303 
oxidative stress induced inflammation or cellular apoptosis. This article provides indirect but clear 
evidence  that  the  presence  of  proteins  belonging  to  the  chitinase  family  among  those  elicited  by 
ovalbumin  in  the  airways  does  not  mean  that  the  inflammation  (asthma)  was  generated  by 
chitin/chitosan  i.e.,  the  substrate  that  they  recognize  (actually  absent  in  this  experimental  work), 
therefore  chitin/chitosan  have  no  capacity  of  inducing  an  inflammatory  reaction  so  severe  as  to 
generate asthma. Moreover, because diesel exhaust particles are ubiquitous and everybody is exposed 
to  their presence,  it is  unimaginable that  occasional  chitin powder  inhalation promote detrimental 
effect more severe than those of diesel exhaust particles. In that article, the proteins mentioned result to 
be useful oxidative markers [81].  
   
6. Current Research Trends 
 
Li  G.P.  et  al.  used  chitosan  nanoparticles  containing  plasmid  DNA  encoding  house  dust  mite 
allergen  for  oral  vaccination  of  mice.  The  DNA  was  fully  complexed  into  chitosan-DNA 
nanoparticles, suggesting a 100% encapsulation efficiency, a further advantage of chitosan being that it 
provides significant protection to the plasmid. The orally administered chitosan nanoparticles induced 
IFN-gamma in serum and prevented subsequent Th2 cell-regulated specific IgE responses [89]. 
Atopy, or atopic syndrome, is an allergic hypersensitivity subject to hereditary influences. The 
aberrant expression of chitinase 3-like-1 (CHI3L1) is involved in the pathogenesis of inflammatory 
and allergic diseases. The genetic contribution of CHI3L1 gene to atopy was investigated by Sohn et 
al.  using  an  integrated  population  genetic  and  molecular  analysis:  the  results  indicated  that  the 
polymorphism in the CHI3L1 promoter region is associated with the risk of atopy [90].  
Several  authors  sustained  these  views  and  concluded  that  more  works  using  knockout  mice, 
recombinant chitinases and siRNA technology are required to investigate a potential role of chitinases 
in the pathogenesis of asthma [68]. For asthma therapy, structural details of AMCase will help guide 
the future design of specific and potent AMCase inhibitors such as methylallosamidin [91].  
In their most recent review on this topic, Seibold and Burchard conclude that "interaction between 
many researchers examining diverse aspects of chitin-chitinase biology is needed including human 
studies  (chitinase  expression,  genetics  and  biochemistry)  coupled  with  epidemiological  studies  of 
chitin exposure and mouse studies of chitinase biology" [92]. Of course, researchers should also be 
aware  of  the  fact  that  chitins  and  chitosans  represent  a  single  aminated  polysaccharide  whose 
biological performances depend not only on the degree of acetylation, but also on the acetylation 
pattern, the degree of crystallinity, the average molecular weight and its polydispersity, among other 
parameters. For example, the susceptibility of chitins/chitosans to hydrolysis by lysozyme is high in a 
narrow  range  of  acetylation  values,  optimum  for  certain  acetylation  patterns,  but  modest  or  nil 
otherwise. 
 
7. Trends in Major Biomedical Fields 
 
As discussed above, the most refined techniques are being used to throw light on the biochemical 
reactions that involve chitin in certain physiological microenvironments. Thus, chitin was administered 
to animals in a variety of ways, i.e., nasally, orally, intraperitoneally, or directly to the eyes and to the Mar. Drugs 2010, 8 
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lungs. Of course, in the area of controlled drug delivery, a remarkably large scientific production is 
based on the use of drug vehicles administered in the same ways: thus, relatively large amounts of 
chitosan accompany therapeutic doses of drugs. 
In said publications, there is no mention of any adverse effect of chitosan in terms of allergy or 
severe inflammation, rather occasional appreciation of the immunostimulating action of chitosan can 
be found, particularly when the studies concern the targeted delivery to tumors and metastases. The 
following  selected  references  concerning  the  delivery  of  a  drug  via  various  routes  support  this 
statement. 
Ocular delivery: In a review article, Paolicelli et al. provided the reader with a description of the 
advances  made  in  the  ocular  delivery  of  bioactive  compounds  by  means  of  chitosan-based 
nanosystems,  resulting  in  innovative  ocular  nanomedicines  with  significant  impact  on  clinical  
practice [93]. 
Targeted  delivery  to  tumors:  Chitosan  nanoparticles  incorporating  anticancer  drugs  such  as 
doxorubicin are suitable for targeting the tumors and for reducing the systemic cytotoxicity of the 
drugs. Chitosan on its own inhibits growth of cancer cells and induces apoptosis of bladder tumor cells 
via caspase-3 activation. According to Tan et al. who reviewed the literature on this topic, chitosan is 
offering  serious  perspectives  of  advances  in  the  encapsulation  of  this  class  of  drugs  leading  to 
increased rates of tumor cell death or tumor size reduction [94]. 
Nasal delivery: Intranasal administration of PEG-g-chitosan nanoparticles to rabbits enhanced the 
absorption of insulin by the nasal mucosa to a greater extent than a suspension of insulin-PEG-g-
chitosan and control insulin solution. PEG-g-chitosan nanoparticles are promising vehicles for insulin 
transport through the nasal mucosa thanks to their mucoadhesion, cationicity, biodegradability and 
safety [81]. 
Vaginal delivery: Perioli et al. prepared vaginal mucoadhesive tablets including the bioadhesive 
polymers  chitosan  and  polyvinylpyrrolidone  in  1:1  ratio.  Hydration,  mucoadhesion,  metronidazole 
release  and  antibacterial  activity  were  the  most  important  characteristics  of  tablets  together  with 
suitable  compactness  and  hardness  [95].  Chitosan  citrate  favored  penetration  enhancement  and 
peptidase inhibition [96].  
Oral administration: The most recent review on oral drug delivery with the aid of chitosan is the 
one by Werle et al. [97]. A book chapter on the oral administration of chitosan viewed as a dietary 
supplement and a food technology commodity was published [98]. Li F. et al. demonstrated that a 
sustainable  increase  of  TGF-beta  protein  in  mouse  intestinal  tissue  can  be  induced  after  oral 
administration by gavage of a TGF-beta expressing DNA vector packed in chitosan nanoparticles [99]. 
Concomitantly, a significant amelioration of ovalbumin-induced food allergy symptoms was observed. 
Delivery to the colon: The polyelectrolyte complex formed by sodium cellulose sulfate and chitosan 
is a drug carrier for a colon-specific delivery, that can be activated by the colonic microflora: this 
promising system [100] is just an example among the many publications on this specific matter. 
Wound  dressing:  The  most  exhaustive  and  recent  reviews  have  been  published  by  Muzzarelli 
[101,102]. It is amply demonstrated that the massive use of chitin and chitosan in the form of freeze-
dried  materials,  elaborated  conduits,  scaffolds,  hydrogels  and  more,  are  useful  for  the  healing  of 
wounded soft tissue, bone, nerve and cartilage. In experimental and pre-clinical surgical trials, the use 
of chitin/chitosan and their derivatives has never led to allergies or other diseases. Mar. Drugs 2010, 8 
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Gene therapy: At present, the most elaborated application of chitosan in the area of drug delivery is 
the delivery of genetic material for gene therapy [103,104]. The large number of recent publications 
testify that chitosan is exempt from undesirable properties. 
 
8. Conclusions 
 
This review shows that chitin and chitosan are endowed with immunoadjuvant capacities that were 
discovered nearly 30 years ago and were confirmed in subsequent years. It also shows that the current 
research relevant to chitin on asthma and allergy does not adequately take into consideration certain 
interdisciplinary  aspects,  so  that  misunderstandings  are  possible  due  to  questionable  assumptions, 
omission of essential documentation, and approximate characterization of materials. Sources of errors 
have been spotted in some of the most recent articles. It is presently unwise to interpret chitin as an 
allergenic substance, more clinical and genetic research being needed. Crab, shrimp, prawn and lobster 
chitins, as well as chitosans of all grades, once purified, should not be considered as "crustacean 
derivatives" because the isolation procedures have removed proteins, fats and other contaminants to 
such an extent as to permit to classify them as chemicals regardless of their origin. 
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